This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F65269705%3A_____%2F10%3A%230001006%21RIV11-MZ0-65269705/
n11http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n17http://linked.opendata.cz/ontology/domain/vavai/
n16http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n13http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n4http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F65269705%3A_____%2F10%3A%230001006%21RIV11-MZ0-65269705
rdf:type
skos:Concept n17:Vysledek
dcterms:description
Nucleophosmin (NPM1) mutations in exon 12 are the most common genetic alternation in cytogenetically normal AML (CN-AML). In this study, we have evaluated a novel, DNAbased real-time quantitative polymerase chain reaction (RQ-PCR) for the detection of three of the most commonly occurring mutations (A,B,D) and for six rare patient-specific mutation types, which represent 28% of all of the NPM1 mutations in our group of 25 CN-AML patients. Furthermore, the prognostic relevance of NPM1- based monitoring of minimal residual disease (MRD) in peripheral blood (PB), bone marrow (BM), and in specific cell subsets (CD341, CD342, CD34dim) of BM were evaluated. In 80% of the evaluable patients, a molecular relapse preceded a hematological relapse. Moreover, in this subset of patients, the molecular relapse occurred at a median of 97 days before the hematological relapse. Our analysis showed a strong correlation between BM and PB as well as a high copy number of mutated NPM1 in CD341 BM cells. Nucleophosmin (NPM1) mutations in exon 12 are the most common genetic alternation in cytogenetically normal AML (CN-AML). In this study, we have evaluated a novel, DNAbased real-time quantitative polymerase chain reaction (RQ-PCR) for the detection of three of the most commonly occurring mutations (A,B,D) and for six rare patient-specific mutation types, which represent 28% of all of the NPM1 mutations in our group of 25 CN-AML patients. Furthermore, the prognostic relevance of NPM1- based monitoring of minimal residual disease (MRD) in peripheral blood (PB), bone marrow (BM), and in specific cell subsets (CD341, CD342, CD34dim) of BM were evaluated. In 80% of the evaluable patients, a molecular relapse preceded a hematological relapse. Moreover, in this subset of patients, the molecular relapse occurred at a median of 97 days before the hematological relapse. Our analysis showed a strong correlation between BM and PB as well as a high copy number of mutated NPM1 in CD341 BM cells.
dcterms:title
Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations
skos:prefLabel
Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations
skos:notation
RIV/65269705:_____/10:#0001006!RIV11-MZ0-65269705
n3:aktivita
n15:V n15:Z
n3:aktivity
V, Z(MSM0021622430)
n3:cisloPeriodika
12
n3:dodaniDat
n14:2011
n3:domaciTvurceVysledku
n11:5378605 n11:7654383 n11:4500970 n11:8223300 n11:4376285 n11:1167197 n11:4585623 n11:3715434
n3:druhVysledku
n12:J
n3:duvernostUdaju
n13:S
n3:entitaPredkladatele
n6:predkladatel
n3:idSjednocenehoVysledku
272484
n3:idVysledku
RIV/65269705:_____/10:#0001006
n3:jazykVysledku
n9:eng
n3:klicovaSlova
minimal residual disease
n3:klicoveSlovo
n10:minimal%20residual%20disease
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[59EFB514215D]
n3:nazevZdroje
American Journal of Hematology
n3:obor
n4:FD
n3:pocetDomacichTvurcuVysledku
8
n3:pocetTvurcuVysledku
8
n3:rokUplatneniVysledku
n14:2010
n3:svazekPeriodika
85
n3:tvurceVysledku
Dvořáková, Dana Ježíšková, Ivana Mayer, Jiří Ráčil, Zdeněk Palásek, Ivo Protivánková, Markéta Lengerová, Martina Rázga, Filip
n3:wos
000285165300004
n3:zamer
n16:MSM0021622430
s:issn
0361-8609
s:numberOfPages
4